{"id":"NCT00396032","sponsor":"Genentech, Inc.","briefTitle":"A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis Catheters","officialTitle":"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis Catheters","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-10","primaryCompletion":"2008-12","completion":null,"firstPosted":"2006-11-06","resultsPosted":"2010-06-03","lastUpdate":"2010-06-03"},"enrollment":150,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Dysfunctional Hemodialysis Catheters"],"interventions":[{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"tenecteplase","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"This was a Phase III, randomized, double-blind, placebo-controlled study conducted at 37 centers in the United States. 150 subjects â‰¥ 16 years of age who required hemodialysis (HD) and had a dysfunctional HD catheter were enrolled in the study.","primaryOutcome":{"measure":"Percentage of Subjects Who Had Treatment Success With Respect to Blood Flow Rate (BFR) at Visit 1","timeFrame":"Visit 1 of HD treatment","effectByArm":[{"arm":"Tenecteplase","deltaMin":21.6,"sd":null},{"arm":"Placebo","deltaMin":5.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0044"},{"comp":"OG000 vs OG001","p":"0.0035"}]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":20},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["20133491"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":74},"commonTop":["Nausea","Vomiting","Thrombosis in Device","Abdominal Pain Upper","Chills"]}}